ZA200903835B - Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction - Google Patents

Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction

Info

Publication number
ZA200903835B
ZA200903835B ZA200903835A ZA200903835A ZA200903835B ZA 200903835 B ZA200903835 B ZA 200903835B ZA 200903835 A ZA200903835 A ZA 200903835A ZA 200903835 A ZA200903835 A ZA 200903835A ZA 200903835 B ZA200903835 B ZA 200903835B
Authority
ZA
South Africa
Prior art keywords
testosterone
treatment
sexual dysfunction
ht1a agonist
ht1a
Prior art date
Application number
ZA200903835A
Other languages
English (en)
Inventor
Jan Johan Adriaan Tuiten
Johannes Martinus Maria Bloemers
Lange Robertus Petrus Johannes De
Original Assignee
Emotional Brain Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emotional Brain Bv filed Critical Emotional Brain Bv
Publication of ZA200903835B publication Critical patent/ZA200903835B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
ZA200903835A 2006-11-03 2007-11-02 Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction ZA200903835B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06076976A EP1925307A1 (fr) 2006-11-03 2006-11-03 Utilisation de 3-alpha-androstanediol pour le traitement des dysfonctions sexuelles

Publications (1)

Publication Number Publication Date
ZA200903835B true ZA200903835B (en) 2010-10-27

Family

ID=37846101

Family Applications (3)

Application Number Title Priority Date Filing Date
ZA200903836A ZA200903836B (en) 2006-11-03 2007-11-02 Use of 3-alpha-androstanediol, optionally in combination with a PDE5 inhibitor, in the treatment of sexual dysfunction
ZA200903837A ZA200903837B (en) 2006-11-03 2007-11-02 Use of 3-Alpha-androstanediol, optionally in combination with A-5-HT1A agonist, in the treatment of sexual dysfunction
ZA200903835A ZA200903835B (en) 2006-11-03 2007-11-02 Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ZA200903836A ZA200903836B (en) 2006-11-03 2007-11-02 Use of 3-alpha-androstanediol, optionally in combination with a PDE5 inhibitor, in the treatment of sexual dysfunction
ZA200903837A ZA200903837B (en) 2006-11-03 2007-11-02 Use of 3-Alpha-androstanediol, optionally in combination with A-5-HT1A agonist, in the treatment of sexual dysfunction

Country Status (28)

Country Link
US (10) US8575139B2 (fr)
EP (5) EP1925307A1 (fr)
JP (8) JP2010509211A (fr)
KR (6) KR101578224B1 (fr)
CN (6) CN101563086B (fr)
AU (3) AU2007314734B2 (fr)
BR (3) BRPI0717963A2 (fr)
CA (3) CA2668317C (fr)
CY (1) CY1117191T1 (fr)
DK (1) DK2086544T3 (fr)
ES (1) ES2561946T3 (fr)
HK (1) HK1135038A1 (fr)
HR (1) HRP20160108T1 (fr)
HU (1) HUE026752T2 (fr)
IL (5) IL198460A (fr)
ME (1) ME02410B (fr)
MX (3) MX2009004696A (fr)
NO (3) NO343597B1 (fr)
NZ (3) NZ577390A (fr)
PH (2) PH12014501440A1 (fr)
PL (1) PL2086544T3 (fr)
PT (1) PT2086544E (fr)
RS (1) RS54541B1 (fr)
RU (4) RU2491073C2 (fr)
SI (1) SI2086544T1 (fr)
UA (4) UA101948C2 (fr)
WO (3) WO2008054213A2 (fr)
ZA (3) ZA200903836B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1750766T3 (pl) 2004-05-11 2013-12-31 Eb Ip Lybrido B V Preparaty farmaceutyczne i ich zastosowania do leczenia zaburzeń seksualnych u kobiet
EP1790343A1 (fr) * 2005-11-11 2007-05-30 Emotional Brain B.V. Compositions pharmaceutiques et leur utilisation pour le traitement des dysfonctions sexuelles chez la femme
EP1925307A1 (fr) 2006-11-03 2008-05-28 Emotional Brain B.V. Utilisation de 3-alpha-androstanediol pour le traitement des dysfonctions sexuelles
EP2266567A1 (fr) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Composition pharmaceutique comprenant de Cetrorelix e d'inhibiteurs de PDE V pour le traitement des étas dépendants de l'hormone sexuel
EP2266568A1 (fr) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Composition pharmaceutique comprenant d'antagonistes de LHRH et d'inhibiteurs de PDE V pour le traitement des états dépendants de l'hormone sexuel
JP6121990B2 (ja) * 2011-05-13 2017-04-26 イービー アイピー ハイブリタブス ビー.ブイ. 薬物送達システム
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
JP5828923B2 (ja) 2014-01-30 2015-12-09 国立大学法人高知大学 ニッケル粉の製造方法
US10471514B2 (en) 2014-02-21 2019-11-12 Kochi University, National University Corporation Method for producing nickel powder
JP6406613B2 (ja) 2014-04-15 2018-10-17 住友金属鉱山株式会社 含有する炭素及び硫黄の濃度を低減するニッケル粉の製造方法
CN103947533B (zh) * 2014-05-15 2015-12-16 青岛理工大学 生长环境可控的磁化水工厂化豆芽菜生产系统
RU2600845C2 (ru) 2014-07-04 2016-10-27 Общество С Ограниченной Ответственностью "Консорциум-Пик" Применение производных оксатриазолий-5-олата для лечения сексуальных расстройств
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3251436A (en) * 1965-03-16 1966-05-17 Dayton Steel Foundry Co Spot-type disk brake
US3976776A (en) * 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
AU577802B2 (en) * 1983-10-17 1988-10-06 Duphar International Research B.V. Blood-pressure lowering piperazine derivatives
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4640921A (en) 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US5015646A (en) * 1987-08-28 1991-05-14 Bristol-Myers Squibb Co. Pharmaceutically useful polymorphic modification of buspirone
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
CA1335106C (fr) 1989-02-27 1995-04-04 John Mehnert Schaus 2-amino-1,2,3,4-tetrahydronaphtalenes a substituants sur le cycle
US5447912A (en) 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US5565466A (en) 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
JP3455544B2 (ja) 1994-06-02 2003-10-14 リガ ダン 抗ストレス剤、抗機能障害剤および抗老化剤、ならびに該薬剤の製造法
RU2152787C2 (ru) 1994-06-02 2000-07-20 Дан Рига Лекарство против стресса, против снижения уровня активности и против старения и способ его получения
AU4844396A (en) 1995-03-01 1996-09-18 Kyowa Hakko Kogyo Co. Ltd. Imidazoquinazoline derivatives
NZ305560A (en) 1995-03-14 1998-11-25 Vivus Inc Method for preventing erectile dysfunction by administering vasoactive agent, particularly a prostaglandin, kit therefor
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
AU5671496A (en) * 1995-05-15 1996-11-29 Beth Israel Hospital Use of dihydrotestosterone compounds for treating male sexual dysfunction
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US6242198B1 (en) 1996-07-25 2001-06-05 Cambridge Neuroscience, Inc. Methods of treatment of eye trauma and disorders
ATE315931T1 (de) * 1997-06-23 2006-02-15 Cellegy Pharma Inc Microdosistherapie von gefässbedingten erscheinungen durch no-donoren
US20020013304A1 (en) 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
US20040014761A1 (en) 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
EP1027057A4 (fr) 1997-10-28 2003-01-02 Vivus Inc Traitement du dysfonctionnement sexuel chez la femme
US6246436B1 (en) * 1997-11-03 2001-06-12 Agilent Technologies, Inc Adjustable gain active pixel sensor
TW542719B (en) 1998-02-23 2003-07-21 Pfizer Res & Dev Method of treating impotence due to spinal cord injury
US6403605B1 (en) * 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
WO2000066114A1 (fr) 1999-04-30 2000-11-09 Lilly Icos Llc Traitement des troubles de la stimulation sexuelle feminine
US6632419B2 (en) 1999-05-04 2003-10-14 Aradigm Corporation Increasing libido in humans via acute testosterone administration
US7258850B2 (en) 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
US6428769B1 (en) 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
WO2000078328A2 (fr) 1999-06-17 2000-12-28 Armin Johannes Becker UTILISATION D'HORMONE DE CROISSANCE (hGH) POUR TRAITER LES TROUBLES DE LA FONCTION SEXUELLE
RU2180591C2 (ru) 1999-12-24 2002-03-20 Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ Средство для лечения сексуальных дисфункций у мужчин
DE10016548A1 (de) 2000-04-03 2001-10-11 Bayer Ag Polyurethan-Dispersionen
US6313172B1 (en) 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6242436B1 (en) * 2000-06-15 2001-06-05 William Charles Llewellyn Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
EP1315502B1 (fr) 2000-08-30 2010-03-17 Unimed Pharmaceuticals, LLC Methode pour traiter la dyserection et augmenter la libido chez l'homme
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20030139384A1 (en) 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
RU2285519C2 (ru) 2000-09-29 2006-10-20 Солвей Фармасьютикалс Б.В. Фармацевтическая композиция с пролонгированным высвобождением, независимым от ионной силы
US20060287335A1 (en) * 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
IL155775A0 (en) * 2000-12-15 2003-12-23 Pfizer Treatment of male sexual dysfunction
US20020107230A1 (en) 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
WO2002069906A2 (fr) 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Composes et procedes pour le traitement de desordres urogenitaux
EA006154B1 (ru) 2001-03-28 2005-10-27 Пфайзер Инк. N-фенпропилциклопентил-замещенные производные глутарамида в качестве nep ингибиторов при fsad
EP1260225A1 (fr) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. Compositions pharmaceutiques pour le traitement hormonal substitutif
US20030027804A1 (en) 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US20030022875A1 (en) * 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US20040259852A1 (en) 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
WO2005007166A1 (fr) * 2003-07-16 2005-01-27 Pfizer Limited Traitement des dysfonctionnements sexuels
ES2258694T3 (es) * 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
WO2005094827A1 (fr) * 2004-03-30 2005-10-13 Kestrel Pharmaceuticals Inc. Methodes de traitement d'un dysfonctionnement sexuel
AU2005235422B2 (en) 2004-04-22 2011-08-11 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders II
PL1750766T3 (pl) * 2004-05-11 2013-12-31 Eb Ip Lybrido B V Preparaty farmaceutyczne i ich zastosowania do leczenia zaburzeń seksualnych u kobiet
KR20080016552A (ko) * 2005-04-13 2008-02-21 유니메드 파마슈티칼스, 인크. 여성의 테스토스테론 및 관련된 스테로이드의 농도를증가시키는 방법
WO2006127057A1 (fr) 2005-05-24 2006-11-30 Lyle Corporate Drvelopment, Inc. Administration vaginale non systématique d'oestrogène et androgène pour le traitement de dysfonctionnement sexuel
WO2006125642A1 (fr) * 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Procedes et dispositifs d'application transdermique ou transmucosale de testosterone
WO2007054791A2 (fr) 2005-11-08 2007-05-18 L'oréal Glucuronides androgenes en tant que marqueurs d’activite androgenique
EP1790343A1 (fr) 2005-11-11 2007-05-30 Emotional Brain B.V. Compositions pharmaceutiques et leur utilisation pour le traitement des dysfonctions sexuelles chez la femme
EP1925307A1 (fr) * 2006-11-03 2008-05-28 Emotional Brain B.V. Utilisation de 3-alpha-androstanediol pour le traitement des dysfonctions sexuelles
MX2010005925A (es) 2007-11-28 2010-08-02 Ucb Pharma Gmbh Nueva forma polimorfico de rotigotina y proceso para la produccion.

Also Published As

Publication number Publication date
US20190262359A1 (en) 2019-08-29
EP2086544B1 (fr) 2015-12-23
UA103592C2 (uk) 2013-11-11
RU2009120988A (ru) 2010-12-10
CA2668317C (fr) 2016-02-09
KR20160124246A (ko) 2016-10-26
JP6357131B2 (ja) 2018-07-11
KR20150099620A (ko) 2015-08-31
CN101557812A (zh) 2009-10-14
UA101948C2 (uk) 2013-05-27
KR20090111803A (ko) 2009-10-27
NZ577393A (en) 2012-11-30
JP5748238B2 (ja) 2015-07-15
NO343597B1 (no) 2019-04-08
CA2668320A1 (fr) 2008-05-08
JP2017132809A (ja) 2017-08-03
UA100119C2 (uk) 2012-11-26
MX2009004696A (es) 2009-06-05
NZ577390A (en) 2012-12-21
PH12014501440A1 (en) 2016-02-01
RU2646447C2 (ru) 2018-03-05
JP2010509212A (ja) 2010-03-25
EP2937086A1 (fr) 2015-10-28
JP2015157849A (ja) 2015-09-03
KR20090111802A (ko) 2009-10-27
HRP20160108T1 (hr) 2016-03-25
MX2009004695A (es) 2009-06-05
EP1925307A1 (fr) 2008-05-28
CA2668316A1 (fr) 2008-05-08
NO20092143L (no) 2009-07-02
WO2008054214A3 (fr) 2009-04-09
US8653051B2 (en) 2014-02-18
US20160082018A1 (en) 2016-03-24
KR101578224B1 (ko) 2015-12-16
MX2009004693A (es) 2009-06-05
CA2668320C (fr) 2014-06-10
CA2668317A1 (fr) 2008-05-08
IL248563A0 (en) 2016-12-29
NZ577392A (en) 2012-11-30
WO2008054215A3 (fr) 2009-04-09
IL198461A0 (en) 2010-02-17
US20140038929A1 (en) 2014-02-06
NO20092146L (no) 2009-07-21
US8648060B2 (en) 2014-02-11
US8575139B2 (en) 2013-11-05
CN101563086A (zh) 2009-10-21
US9211334B2 (en) 2015-12-15
KR101796887B1 (ko) 2017-11-10
US10314848B2 (en) 2019-06-11
US20140121190A1 (en) 2014-05-01
CN101563086B (zh) 2013-11-27
CA2668316C (fr) 2014-06-10
NO20092145L (no) 2009-07-21
EP2086544A2 (fr) 2009-08-12
PH12014501821B1 (en) 2016-02-01
ZA200903836B (en) 2010-08-25
AU2007314735A1 (en) 2008-05-08
KR20150038251A (ko) 2015-04-08
CY1117191T1 (el) 2017-04-05
RU2463054C2 (ru) 2012-10-10
JP2010509213A (ja) 2010-03-25
CN103599536A (zh) 2014-02-26
KR20090115113A (ko) 2009-11-04
IL198459A (en) 2016-11-30
WO2008054213A3 (fr) 2009-04-09
EP2086545A2 (fr) 2009-08-12
RU2012125827A (ru) 2013-12-27
PH12014501821A1 (en) 2016-02-01
HK1135038A1 (en) 2010-05-28
WO2008054215A2 (fr) 2008-05-08
AU2007314736A1 (en) 2008-05-08
BRPI0717963A2 (pt) 2013-11-05
ZA200903837B (en) 2010-08-25
AU2007314734B2 (en) 2014-01-30
US9597335B2 (en) 2017-03-21
BRPI0717856A2 (pt) 2013-10-29
DK2086544T3 (en) 2016-02-08
IL198461A (en) 2017-08-31
PL2086544T3 (pl) 2016-07-29
RU2009120992A (ru) 2010-12-10
US20100093680A1 (en) 2010-04-15
AU2007314736B2 (en) 2014-01-23
RS54541B1 (en) 2016-06-30
ME02410B (fr) 2016-09-20
JP2010509211A (ja) 2010-03-25
BRPI0718396A2 (pt) 2013-11-26
IL248563B (en) 2018-11-29
US20120277200A1 (en) 2012-11-01
RU2009120990A (ru) 2010-12-10
UA115647C2 (uk) 2017-12-11
WO2008054213A2 (fr) 2008-05-08
JP2014111608A (ja) 2014-06-19
IL237786A0 (en) 2015-05-31
AU2007314734A1 (en) 2008-05-08
CN104524580A (zh) 2015-04-22
WO2008054214A2 (fr) 2008-05-08
ES2561946T3 (es) 2016-03-01
US20100160270A1 (en) 2010-06-24
CN103381270A (zh) 2013-11-06
RU2491073C2 (ru) 2013-08-27
IL198459A0 (en) 2010-02-17
IL198460A (en) 2016-11-30
US8669242B2 (en) 2014-03-11
RU2464027C2 (ru) 2012-10-20
US20140121189A1 (en) 2014-05-01
PT2086544E (pt) 2016-03-17
CN101573119A (zh) 2009-11-04
US20100152145A1 (en) 2010-06-17
JP2014001235A (ja) 2014-01-09
HUE026752T2 (en) 2016-07-28
AU2007314735B2 (en) 2014-01-16
JP2014055142A (ja) 2014-03-27
IL198460A0 (en) 2010-02-17
US20170157142A1 (en) 2017-06-08
SI2086544T1 (sl) 2016-04-29
EP2086548A2 (fr) 2009-08-12

Similar Documents

Publication Publication Date Title
HK1135038A1 (en) Use of testosterone and a 5-ht1a agonist in the treatment of sexual dysfunction
HK1126212A1 (en) Heterocyclic compounds and uses thereof in the treatment of sexual disorders
PL1912650T3 (pl) Zastosowanie flibanseryny w leczeniu otyłości
EP1909644A4 (fr) Appareil d'insertion et procédés d'utilisation
ZA200902894B (en) Smoothened polypeptides and methods of use
EP2091588A4 (fr) Dispositif cardiaque et ses procédés d'utilisation
IL191160A0 (en) Pyridopyrazine derivatives and use thereof
ZA200902419B (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
IL191280A0 (en) Pharmaceutical combinations comprising testosterone in the treatment of female sexual dysfunction
HK1132882A1 (en) Treatment of comorbid premature ejaculation and erectile dysfunction
ZA200805870B (en) One-way valve and apparatus and method of using the valve
ZA200904755B (en) Use of epothilones in the treatment of osteoporosis and related diseases
GB0603497D0 (en) Device and method of use
GB0618815D0 (en) 809 - Pseudoephedrine in the treatment of acute migraine
GB0503523D0 (en) Ultrasound device and method of use
IL198079A0 (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases